Rayyan
AI-powered systematic review platform that screens thousands of research abstracts for inclusion in reviews.
Overview
Rayyan is an AI-assisted systematic review platform that automates the abstract screening phase of systematic literature reviews. In systematic reviews, researchers must screen thousands of abstracts to identify relevant studies — a process that typically requires two researchers to independently review each abstract to ensure consistency. Rayyan's AI learns from human reviewer decisions and predicts inclusion/exclusion labels for unreviewed abstracts.
The Blind mode allows multiple reviewers to rate abstracts independently before comparing decisions, maintaining the scientific rigour of blinded review while sharing a platform. The machine learning model is trained in real time: as reviewers label abstracts, the AI immediately updates its predictions for remaining papers, prioritising the most likely relevant papers to maximise early discovery.
Rayyan is used by over 300,000 researchers globally and is the most widely used dedicated systematic review tool. It is particularly valuable in systematic reviews of clinical evidence for evidence-based medicine, public health research, and policy development. The platform accelerates the most time-consuming part of the systematic review process without compromising scientific standards.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 8 May 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
Use cases
ASEAN Perspective
Rayyan in Southeast Asia
ASEAN-region availability and pricing notes coming soon. Drop the editorial team a note via /contact/ if you can supply local context (Singapore/Malaysia/Indonesia/Thailand/Vietnam).
Rayyan is a long-standing, trusted platform for collaborative screening in systematic and scoping reviews, with AI-assisted relevance ranking, blind dual screening, duplicate handling and PICO extraction. It is purpose-built for researchers, used widely in academia and medicine, and its free tier plus affordable Pro pricing (~$8-25/user/mo) make it accessible to students and labs, including across ASEAN universities.
It is a specialised research tool, not general-purpose, and premium AI features are gated behind paid seats. The AI accelerates but does not replace expert screening, and the interface, while functional, is utilitarian. For evidence-synthesis work it is one of the best-value options available; outside that workflow it has no relevance.
Notable facts
- Rayyan has processed over 50 million abstract screenings, making it one of the most heavily used academic research tools in existence.
- The platform was developed at the Qatar Computing Research Institute, making it one of the first major AI research tools to emerge from the Middle East.
- Rayyan's AI can reduce abstract screening time by up to 80%, potentially compressing a 6-month systematic review into 6 weeks.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Rayyan's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Rayyan unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Rayyan directly →
Spotted something out of date? Suggest an update →
Alternatives to Rayyan
More in Research & Data
